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Current interventions with proven efficacy, such as glycemic and blood pressure control, dietary protein restriction,
and angiotensin II blockade, slow the progression of chronic kidney disease (CKD); however, whether long-term cessation
of CKD progression is possible remains unclear. Because of the pathogenetic complexity of this condition, multidrug
interventions with the least adverse effects should be investigated as the next step in attempts to stop CKD progression.
Pentoxifylline, a non-selective phosphodiesterase inhibitor with indiscernible toxicity, exerts potent inhibitory effects
against cell proliferation, inflammation, and extracellular matrix accumulation, all of which play important roles in CKD
progression. Pentoxifylline monotherapy markedly reduces proteinuria in patients with membranous nephropathy.
Moreover, limited human studies have proven pentoxifylline efficacy in reducing proteinuria in patients with diabetes
receiving angiotensin-converting enzyme inhibitors, and in patients with nephrotic syndrome secondary to lupus nephritis
despite immunosuppressive therapy. Further clinical trials are necessary to examine whether pentoxifylline can improve
renal outcomes in patients receiving interventions of proven efficacy. [J Chin Med Assoc 2005;68(3):99–105]
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Introduction
Pentoxifylline is a methylxanthine that improves
perfusion in the impaired microcirculation of peripheral
and cerebral vascular beds.1 This hemorheologic acti-
vity mostly involves inhibition of cyclic-3’,5’-
phosphodiesterase (PDE), leading to raised intracellular
cyclic adenosine monophosphate (cAMP) and activation
of protein kinase A (PKA). The superfamily of PDE
isozymes consists of at least 11 gene families: PDE 1 to
PDE 11.2,3 The recent development of selective PDE
isozyme inhibitors has advanced the identification of
the specific role of PDE isozymes in several pathobiologic
processes. Pentoxifylline inhibits PDE 1–5 with IC50
values ranging from 50–200 +M, thereby classifying it
as a non-selective PDE inhibitor.4,5 Notably, pentoxi-
fylline is a safe drug that is usually well tolerated when
administered as the conventional controlled-release
formulation: gastrointestinal symptoms (i.e. nausea
and dyspepsia) and dizziness are the most common
complaints and affect about 3% of patients.1 Besides
its hemorheologic activity, growing evidence has
demonstrated that pentoxifylline has broad-spectrum
effects to slow the progression of chronic kidney disease
(CKD).6–18 Although accumulation of the active
metabolite of pentoxifylline has been documented in
moderate and severe renal dysfunction during multi-
dose pharmacokinetic studies, the clinical significance
of this is unclear. Dosage reductions to 400 mg twice
daily in patients with moderate renal dysfunction, and
to 400 mg once daily in patients with severe renal dys-
function, are recommended.19 This article reviews the
rationale and evidence for the renoprotective effect of
pentoxifylline, and raises some unanswered questions.
Rationale and Evidence for the
Renoprotective Activity of Pentoxifylline
Whatever the initial injury to the kidney, the remaining
S.L. Lin, et al
100 J Chin Med Assoc • March 2005 • Vol 68 • No 3
nephrons undergo adaptive hypertrophy and hyper-
filtration to minimize the functional consequences of
progressive nephron loss.20 However, such adaptation
ultimately leads to a vicious cycle, in which hypertrophy
and hyperfiltration of the remaining nephrons lead to
glomerulosclerosis and glomerular barrier impairment,
which in turn induce tubulointerstitial damage and the
loss of more nephrons.21,22 The adaptive hypertrophy
and hyperfiltration of glomeruli result from increased
expression of growth factors, such as platelet-derived
growth factor (PDGF), transforming growth factor-
`1 (TGF-`1), connective tissue growth factor (CTGF),
and fibroblast growth factor-2 (FGF-2), and from
activation of the renin-angiotensin-aldosterone system
(RAAS).20,23–26 Furthermore, after stimulation by pro-
inflammatory cytokines, angiotensin II and urinary
protein, various chemokines, such as monocyte chemo-
attractant protein-1 (MCP-1), regulated on activation,
normal T cell expressed and secreted (RANTES), and
fractalkine, are secreted; these chemokines subsequently
recruit inflammatory cells into the glomeruli and
interstitium.21,22,27–30 Thus, cell proliferation and
inflammation result in further expression of growth
factors, cytokines, and chemokines, leading to more
and more inflammation, extracellular matrix (ECM)
accumulation and, ultimately, renal fibrosis.
Examination of extracts from nephron segments
and cultured renal cells has shown diverse expression
of PDE isozymes.2 Evidence shows that the PDE 3-
linked cAMP-PKA pathway suppresses mitogenesis,
whereas the PDE 4-linked pathway selectively
modulates the generation of reactive oxygen species
(ROS) in rat mesangial cells, which are considered to
play a central role in the development of glomerulo-
sclerosis.31 Upon activation of the adjacent cAMP-
PKA by selective inhibition of PDE 3, Raf-1 is phos-
phorylated and 14-3-3 proteins bind, blocking Raf-1
recruitment to the plasma membrane and preventing
its activation and downstream mitogenic signal.31,32
Conversely, inhibition of PDE 4 leads to an increase
of another cAMP pool and activates adjacent PKA,
which subsequently decreases nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH) oxidase
assembly and ROS generation via phosphorylating
Rap-1a.33 Inhibitors of PDE 3 and 4 have a suppressive
effect in acute phases or relapses of experimental
mesangial proliferative glomerulonephritis.34 Besides
a suppressive effect on cell proliferation and ROS
generation in glomerulonephritis, PDE 4 inhibitors
decrease de novo synthesis and tissue accumulation of
proinflammatory cytokines, such as tumor necrosis
factor-_ (TNF-_), interleukin-1` (IL-1`), interleukin-
6 (IL-6), and interferon-a (IFN-a), which all play
important roles in CKD progression.35,36 Furthermore,
inhibitors of PDE 3 and 4 inhibit fibroblast activation
and fibrosis progression.37,38 Therefore, various PDE
inhibitors, alone or in combination, can target different
pathogenetic mechanisms, including cell proliferation
and inflammation, and ECM accumulation, and
represent a novel “signal-transduction pharmaco-
therapy” for CKD.
Laboratory evidence
As a non-selective PDE inhibitor, pentoxifylline has
demonstrated potent inhibitory effects on cell pro-
liferation, inflammation, and ECM accumulation.
Pentoxifylline can suppress activation and prolifera-
tion of mesangial cells, lymphocytes, and renal fibro-
blasts, all of which play important roles in renal
fibrosis.9,12,15,16,39–41 Furthermore, pentoxifylline can
downregulate the expression of various cytokines,
including PDGF, FGF-2, TGF-`1, and CTGF, all of
which are important growth factors for cell proliferation
and ECM synthesis in glomerular mesangial cells and
interstitial fibroblasts.12,15,41 With indiscernible
cytotoxicity, pentoxifylline potently inhibits mesangial
cell proliferation by blocking multiple PDGF post-
receptor signaling pathways, including the mitogen-
activated protein kinase (MAPK) and phosphatidyl-
inositol 3-kinase/Akt (PI3K/Akt) pathways.16
Although there is evidence that pentoxifylline can
inhibit cell proliferation independent of PDE inhibi-
tion,42 we have demonstrated that pentoxifylline
interferes with PDGF signaling to mesangial cell
proliferation through PKA activation, a mechanism
similar to that employed in vascular smooth muscle
cells.16,43
In rats, we have demonstrated that pentoxifylline
reduces the accumulation and proliferation of
glomerular macrophages in mesangial proliferative
glomerulonephritis, and the recruitment of macro-
phages, lymphocytes, and major histocompatibility
complex (MHC) class II antigen-positive cells into
remnant kidney interstitium.12,15 We further demon-
strated that pentoxifylline suppresses the increased
expression of TNF-_, intercellular adhesion molecule-
1, MCP-1, RANTES, and osteopontin.12,15,18 These
anti-inflammatory actions are associated with such
renoprotective effects as reduction of proteinuria and
azotemia, and attenuation of glomerular crescents,
sclerosis and interstitial fibrosis.12,15,18 Besides its
growth-inhibitory effect on lymphocytes themselves,40
pentoxifylline potently downregulates MHC class II
antigen expression, and inhibits peripheral mono-
nuclear cell secretion of pro-inflammatory cytokines
and chemokines, including TNF-_, IL-1`, IL-6, IFN-
Pentoxifylline in chronic kidney disease
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a, and MCP-1.14,44–46
In the local environment of the tubulointerstitium,
urinary protein, angiotensin II and TNF-_ stimulate
proximal tubular epithelial cells to secrete chemokines,
MCP-1, RANTES, and fractalkine, which are all im-
portant to the recruitment of inflammatory mono-
nuclear cells into the interstitium.15,28,47,48 Indeed, we
have demonstrated that pentoxifylline reduces upreg-
ulation of MCP-1 in albumin-stimulated or angio-
tensin II-stimulated proximal tubular epithelial cells, a
mechanism that is partly responsible for the attenuation
of MCP-1 expression and interstitial inflammation.15
Pentoxifylline and its metabolites are also reported to
inhibit nuclear factor-gB (NF-gB) activation through
PDE inhibition-dependent and -independent mecha-
nisms.29,46,49,50 In addition, we demonstrated that the
TNF-_-induced activating protein-1 (AP-1) signal is
the target by which pentoxifylline inhibits MCP-1 and
fractalkine production.29,50 Therefore, pentoxifylline is
a potent anti-inflammatory agent capable of amelio-
rating kidney inflammation by acting on various targets,
including the synthesis of pro-inflammatory cytokines
and chemokines, and the growth and activation of
inflammatory mononuclear cells.
Besides its growth-inhibitory effect on cultured
mesangial cells and renal fibroblasts, pentoxifylline
downregulates ECM gene expression and the synthesis
of protein, including types I and III collagen and
fibronectin, in these cells.9,15,41 This downregulatory
effect on ECM genes was accompanied by amelioration
of glomerulosclerosis and interstitial fibrosis, as demon-
strated in the kidneys of animals with experimental
mesangial proliferative glomerulonephritis, crescentic
glomerulonephritis, and remnant kidney.12,15,18
Pentoxifylline also reduces overexpression of
TGF-`1 and CTGF in the remnant kidney, but it has
no direct inhibitory effect on angiotensin II-induction
of TGF-`1 expression in both mesangial cells and
fibroblasts.15 We therefore suggest that TGF-`1
downregulation by pentoxifylline in the remnant kidney
is due to reduced numbers of cells secreting this
growth factor, including infiltrating inflammatory cells,
glomerular mesangial cells, and interstitial fibroblasts.
Indeed, we have demonstrated that pentoxifylline
reduces angiotensin II-induced or TGF-`1-induced
expression of CTGF in cultured mesangial cells and
fibroblasts, and have suggested this as a possible
mechanism for pentoxifylline effect on downregulation
of CTGF expression and attenuation of fibrosis in
remnant kidney.15 Because TGF-`1 also plays important
anti-inflammatory and anti-proliferative roles in
mammalian systems, blockage of its downstream pro-
fibrogenic mediators should be a better strategy for
ameliorating renal fibrosis. CTGF plays a crucial role
in ECM synthesis and epithelial-mesenchymal
transdifferentiation of tubular epithelial cells induced
by TGF-`1, suggesting that blockade of CTGF could
be a selective therapeutic target against renal fibrosis.
Therefore, pentoxifylline is not only an effective, but
also a selective, drug to prevent renal fibrosis.
These beneficial effects of pentoxifylline on different
cell types and animal models are summarized in Tables
1 and 2. In addition, Figure 1 outlines the possible
renoprotective mechanisms of pentoxifylline in the
treatment of CKD.
Clinical evidence
It is well known that pentoxifylline can reduce pro-
teinuria in diabetic patients,6–8,11 in part because of
its hemorheologic action, but also because of its anti-
TNF-_ effect. In a recent study of early type 2 diabetic
nephropathy, in patients receiving treatment with an
angiotensin-converting enzyme (ACE) inhibitor or
angiotensin-receptor blocker (ARB) when pentoxi-
fylline was added, pentoxifylline further reduced urinary
protein and N-acetyl-`-glucosaminidase excretion.17
These findings provide clinical evidence that pen-
toxifylline, combined with RAAS blockade, may further
Table 1. The renoprotective potential of pentoxifylline in cellular models
Cell types Inhibitory effects of pentoxifylline References
Glomerular mesangial cells Cell proliferation; ECM gene expression and protein 9,16
   synthesis; CTGF gene expression; cyclin D1
Renal interstitial fibroblasts Cell proliferation; ECM gene expression and protein 15,41
   synthesis; CTGF gene expression; FGF-2 gene expression
Renal proximal tubular epithelial cells MCP-1 gene expression 15
Macrophages/lymphocytes Cell proliferation; MHC class II antigen expression; 12,15,39,40
   production of TNF-_, IL-1`, IL-6, IFN-a, MCP-1
CTGF = connective tissue growth factor; ECM = extracellular matrix; FGF-2 = fibroblast growth factor-2; IFN-a = interferon-a; IL-1` = interleukin-1`;
IL-6 = interleukin-6; MCP-1 = monocyte chemoattractant protein-1; MHC = major histocompatibility complex; TNF-_ = tumor necrosis factor-_.
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Table 2. The renoprotective effects of pentoxifylline in animal models
Animal models Beneficial effects of pentoxifylline References
Anti-thy1 GN of rats Improves proteinuria and glomerulosclerosis; reduces the numbers 12,16
   of proliferating glomerular mesangial cells and macrophages;
   downregulates gene expression of glomerular MCP-1, ICAM-1, and
   ECM; reduces cyclin D1 expression of glomerular mesangial cells
Remnant nephropathy of rats Attenuates proteinuria, azotemia, glomerulosclerosis, interstitial 15
   inflammation and fibrosis; reduces glomerular cellularity and the
   number of interstitial myofibroblasts; downregulates gene expression
   of cortical MCP-1, PDGF, FGF-2, TGF-`1, CTGF, and collagen
Crescentic GN of rats Attenuates proteinuria and glomerular crescent formation; downregulates 18
   gene expression of cortical TNF-_, ICAM-1, RANTES, MCP-1, OPN,
   and ECM
SLE mice Attenuates proteinuria and renal immune complex deposition; 14
   reduces the production of TNF-_ and IL-1
CTGF = connective tissue growth factor; ECM = extracellular matrix; FGF-2 = fibroblast growth factor-2; GN = glomerulonephritis; ICAM-1 = intercellular
adhesion molecule-1; IL-1 = interleukin-1; MCP-1 = monocyte chemoattractant protein-1; OPN = osteopontin; PDGF = platelet-derived growth factor;
RANTES = regulated on activation, normal T cell expressed and secreted; SLE = systemic lupus erythematosus; TGF-`1 = transforming growth
factor-`1; TNF-_ = tumor necrosis factor-_.
Figure 1. The renoprotective mechanisms of pentoxifylline in the
treatment of chronic kidney disease. A indicates stimulation,
secretion, or expression; PTX indicates that the pathway is
inhibited by pentoxifylline. CTGF = connective tissue growth
factor; MCP-1 = monocyte chemoattractant protein-1; MHC =
major histocompatibility complex; PDGF = platelet-derived growth
factor; TGF-`1 = transforming growth factor-`1.
Table 3. Clinical evidence for the renoprotective effects of pentoxifylline
Renal diseases Beneficial effects of pentoxifylline References
Diabetic nephropathy Reduces proteinuria; reduces urinary N-acetyl-`-glucosaminidase 6–8,11,17
   excretion; improves glomerular filtration rate; reduces serum
   and urinary TNF-_
Membranous nephropathy Reduces proteinuria; reduces plasma and urinary TNF-_ 13
Lupus nephritis Reduces proteinuria 51
Chronic glomerulonephritis Reduces proteinuria; reduces urinary TNF-_ Manuscript in
  preparation
TNF-_ = tumor necrosis factor-_.
protect the kidney.
Besides its beneficial effect against diabetic nephro-
pathy, pentoxifylline also has anti-proteinuric activity
in patients with refractory nephrotic syndrome due to
membranous nephropathy or lupus nephritis:13,51
remission of proteinuria was achieved and serum and
urinary TNF-_ levels were decreased. We also found
that pentoxifylline significantly reduced urinary protein
and TNF-_excretion in non-diabetic patients with
non-nephrotic glomerular proteinuria (manuscript in
preparation). Therefore, pentoxifylline has therapeutic
potential in preventing the progression of most kidney
diseases (Table 3).
The Next Treatments for CKD
Four principal interventions, including intensive
glycemic control in diabetic patients, stringent blood
pressure control, restriction of dietary protein intake,
Pentoxifylline in chronic kidney disease
103J Chin Med Assoc • March 2005 • Vol 68 • No 3
and angiotensin II blockade, slow the progression of
CKD.52–60 Physicians can apply these interventions to
actively prevent CKD progression in most cases.
However, the ultimate intervention to prevent CKD
progression in the long term remains unclear. Because
of the pathogenetic complexity of CKD, multidrug
interventions with the least adverse effects should be
the next step towards potentially halting CKD
progression.15,61–67 Experimental and limited human
studies have demonstrated the potential of added
pentoxifylline to further improve existing CKD therapy
(i.e. when used together with currently available
interventions). However, recent trials of ARBs in
patients with type 2 diabetic nephropathy required
more than 1,500 participants to achieve a statistically
meaningful result after about 3 years.59,60 The efficacy
of pentoxifylline may be hard to prove in large-scale
clinical trials, against a background of ACE inhibitor
or ARB therapy, and using conventional renal-
progression endpoints such as death, end-stage renal
disease, or halving of glomerular filtration rate.
Therefore, before proteinuria or any other surrogate
marker is proved to be a solid index of effective
therapy, further studies should be performed to translate
present evidence into established practice.
Because of high event rates, relatively few patients
with a high risk of CKD progression need to be
entered into clinical trials. Thus, we are conducting a
clinical trial to determine whether pentoxifylline can
prevent one of the conventional renal endpoints from
being reached in high-risk individuals receiving
background RAAS-blocking therapy. Results from
this study will answer the question of whether
pentoxifylline further improves renal outcomes in
CKD patients already receiving interventions of proven
efficacy.
In conclusion, the renoprotective potential of
pentoxifylline has been uncovered in CKD patients.
Further clinical trials are necessary to examine whether
pentoxifylline can improve renal outcomes in patients
already receiving interventions of proven efficacy. We
believe that combining pentoxifylline with currently
available interventions will be the next approach towards
potentially halting the progression of CKD.
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